Prescribing information


Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.


How can I offer my adult psoriasis patients the chance to look, move and feel better?

Psoriasis is caused by systemic inflammation, with manifestations that can affect more than just the skin. These manifestations can have a dramatic impact on the way patients live their lives.2,3  Explore the data below to understand how Cosentyx has shown fast and long-term relief.

CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA psoriatic arthritis.

Rate this content: 
No votes yet
UK | November 2021 | 158789

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]